Benign Prostatic Hyperplasia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Benign Prostatic Hyperplasia stocks.

Benign Prostatic Hyperplasia Stocks Recent News

Date Stock Title
May 21 SBFM Sunshine Biopharma reports Q1 results
May 21 LLY Microcap Mangoceuticals doubles on plan to sell cheap oral GLP-1 weight loss meds
May 21 LLY Eli Lilly inks radiopharma deal worth up to $1.1B with Aktis
May 21 SBFM Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%
May 21 LLY More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure
May 21 LLY Eli Lilly’s tirzepatide cleared for diabetes treatment in China
May 21 LLY Eli Lilly's diabetes drug tirzepatide gets approval in China
May 20 BSX Philips' (PHG) Reports Positive AI-Powered Cardiac Study Data
May 20 BSX Boston Scientific (BSX) Reaches 52-Week High: What's Aiding It?
May 20 BSX Boston Scientific (BSX) mCRM System Study Outcome Favorable
May 20 LLY Magnificent Seven? Just Two Members Clear This Bar
May 20 BSX Pulsed field ablation poised for fast adoption, analysts say
May 20 LLY The Zacks Analyst Blog Highlights Microsoft, Eli Lilly, Costco and Koss
May 20 BSX Boston Scientific hits all endpoints in CRM trial
May 20 BSX UK backs use of cancer treatment offered by Boston Scientific
May 20 LLY The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
May 20 BSX J&J posts latest Varipulse data while awaiting FDA review
May 19 LLY SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued?
May 19 LLY Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
May 18 BSX Boston Scientific succeeds in pivotal trial for leadless pacemaker
Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.The cause is unclear. Risk factors include a family history, obesity, type 2 diabetes, not enough exercise, and erectile dysfunction. Medications like pseudoephedrine, anticholinergics, and calcium channel blockers may worsen symptoms. The underlying mechanism involves the prostate pressing on the urethra thereby making it difficult to pass urine out of the bladder. Diagnosis is typically based on symptoms and examination after ruling out other possible causes.Treatment options including lifestyle changes, medications, a number of procedures, and surgery. In those with mild symptoms weight loss, exercise, and decreasing caffeine intake is recommended. In those with more significant symptoms medications may include alpha blockers such as terazosin or 5α-reductase inhibitors such as finasteride. Surgical removal of part of the prostate may be carried out in those who do not improve with other measures. Alternative medicine, such as saw palmetto, does not appear to help.About 105 million people are affected globally. BPH typically begins after the age of 40. Half of males age 50 and over are affected. After the age of 80 about 90% of males are affected. Although prostate specific antigen levels may be elevated in males with BPH, the condition does not increase the risk of prostate cancer.

Browse All Tags